Use of Continuous Glucose Monitoring in Patient with Coronary Artery Disease and Type 2 Diabetes Mellitus: Case Report

Keywords: risk factors, revascularization of coronary arteries, hypoglycemia, hypoglycemic therapy, sodium-glucose cotransporter 2 inhibitor, glycated hemoglobin

Abstract

We present a clinical case of continuous monitoring in a patient with coronary artery disease and concomitant type 2 diabetes mellitus. A 75-year-old patient with a history of coronary artery bypass graft surgery more than 10 years ago was admitted to the Ukrainian Children’s Cardiac Center, Clinic for Adults with complaints of angina pectoris. The patient had progressive atherosclerotic lesions of the coronary arteries despite of controlled risk factors (normal weight, regular monitoring of blood pressure, lipid profile, blood glucose and glycated hemoglobin [HbA1c], active lifestyle). The heart team decided to perform percutaneous coronary intervention which resulted in thrombolysis in myocardial infarction (TIMI) 3 flow.

During continuous glycemic monitoring in the patient we detected nocturnal asymptomatic episodes of hypoglycemia. Together with endocrinologist we performed adjustment of drug treatment: the hypoglycemic drug sulfonylurea was changed to a sodium-glucose cotransporter 2 inhibitor. Three months later we repeated monitoring of glycemia and no episodes of hypoglycemia were detected, HbA1c was 6.4%.

Conclusions. This case report shows that continuous glucose monitoring is an optimal method for diagnosing silent episodes of hypoglycemia and should be considered along with the control of the HbA1c level as an important auxiliary method for controlling type 2 diabetes mellitus in patients with cardiovascular diseases. Because glucose-lowering drugs such as sulfonylureas are risk factors for hypoglycemic episodes in patients with coronary artery disease, they should be changed to more effective and safer medications if possible.

References

  1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107-11. https://doi.org/10.2991/jegh.k.191028.001
  2. Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014;32(3):439-55. https://doi.org/10.1016/j.ccl.2014.04.001
  3. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B; DCCT/EDIC Research Group. Diabetes control and complications trial/ epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62(12):3976-86. https://doi.org/10.2337/db13-1093
  4. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther. 2017;8(4):863-73. https://doi.org/10.1007/s13300-017-0280-5
  5. Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP; EXAMINE Investigators. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes Obes Metab. 2017;19(5):664-71. https://doi.org/10.1111/dom.12871
  6. Lee AK, Warren B, Lee CJ, Huang ES, Sharrett RA, Coresh J, Selvin E. Association of severe hypogylcemia with cardiovascular disease and all-cause mortality in older adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study [abstract]. Circulation. 2017;135:A43. https://doi.org/10.1161/circ.135.suppl_1.43
  7. Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and Cardiovascular Risk: Is There a Major Link? Diabetes Care. 2016;39 (Suppl 2):S205-9. https://doi.org/10.2337/dcS15-3014
  8. Colling C, Atlas SJ, Wexler DJ. Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Diabetes Care. 2021 44(6):1443-6. https://doi.org/10.2337/dc21-0013
  9. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-S84. https://doi.org/10.2337/dc21-S006
  10. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19. https://doi.org/10.1186/1475-2840-10-19
  11. Morales J, Schneider D. Hypoglycemia. Am J Med. 2014;127(10 Suppl):S17-24. https://doi.org/10.1016/j.amjmed.2014.07.004
Published
2022-03-23
How to Cite
1.
Mankovsky GB, Dzhun YY, Marushko YY, Saienko YA, Rudenko NM, Mankovsky BM. Use of Continuous Glucose Monitoring in Patient with Coronary Artery Disease and Type 2 Diabetes Mellitus: Case Report. ujcvs [Internet]. 2022Mar.23 [cited 2024Dec.26];30(1):83-8. Available from: http://cvs.org.ua/index.php/ujcvs/article/view/473